Cannabis drug trial for mind tumours will get go-ahead

Sativex is a cannibanoid medecine manufactured by GW Pharmaceuticals. This mouth spray has just received approval to be launched on the French market, for limited use on patients suffering from multiple sclerosis. (Photo by: BSIP/Universal Images Group via Getty Images)

Sativex is a cannibanoid medecine manufactured by GW Pharmaceuticals. (BSIP/Universal Images Group by way of Getty Images)

A ‘world first’ trial assessing a cannabis-based drug to deal with an aggressive type of mind most cancers is to go forward, a charity has introduced.

Members of the general public backed an enchantment by the Brain Tumour Charity to boost £400,000 to fund the three-year trial.

Olympic champion Tom Daley additionally backed the marketing campaign.

The gold medal-winning diver’s father Robert died aged 40 from a mind tumour in 2011.

The examine, led by an professional on the University of Leeds, will take a look at whether or not including Sativex – an oral spray containing cannabinoids – to chemotherapy may lengthen life for individuals identified with a recurrent glioblastoma.

The trial will start recruiting 230 sufferers at 15 hospitals throughout the UK early subsequent yr.

Sativex is a cannibanoid medecine manufactured by GW Pharmaceuticals. This mouth spray has just received approval to be launched on the French market, for limited use on patients suffering from multiple sclerosis.. (Photo by: BSIP/Universal Images Group via Getty Images)

Sativex mouth spray has simply obtained approval to be launched on the French market, for restricted use on sufferers affected by a number of sclerosis. (BSIP/Universal Images Group by way of Getty Images)

The situation is the most typical and aggressive type of mind most cancers, and round 2,200 individuals are identified every year in England alone.

Even after intensive therapy common survival is barely 12 to 18 months after analysis, the Brain Tumour Charity mentioned.

If the trial proves profitable, researchers hope it may symbolize one of many first additions to NHS therapy for glioblastoma sufferers in additional than a decade.

It will measure whether or not including Sativex to chemotherapy extends the general size of sufferers’ lives, delays the development of their illness, or improves high quality of life.

The precept investigator on the examine, Susan Short, professor of scientific oncology and neuro-oncology on the University of Leeds, mentioned: ‘The therapy of glioblastomas stays extraordinarily difficult.

‘Even with surgical procedure, radiotherapy and chemotherapy, almost all of those mind tumours regrow inside a yr, and sadly there are only a few choices for sufferers as soon as this happens.

‘Cannabinoids have well-described results within the mind and there was lots of curiosity of their use throughout completely different cancers for a very long time now.

‘Glioblastoma brain tumours have been shown to have receptors to cannabinoids on their cell surface, and laboratory studies on glioblastoma cells have shown these drugs may slow tumour growth and work particularly well when used with temozolomide.’

Cannabis being grow for medical use, France. (Photo by: BSIP/Universal Images Group via Getty Images)

Cannabis being develop for medical use in France. (BSIP/Universal Images Group by way of Getty Images)

‘It’s actually thrilling that we’re now on the level the place we are able to run a definitive, well-designed examine that may inform us the reply as to if these brokers may assist deal with probably the most aggressive type of mind tumour.

‘Having recently shown that a specific cannabinoid combination given by oral spray could be safely added to temozolomide chemotherapy, we’re actually excited to construct on these findings to evaluate whether or not this drug may assist glioblastoma sufferers reside longer in a serious randomised trial.’

Dr David Jenkinson, interim chief government on the Brain Tumour Charity, added: ‘We know there was vital curiosity amongst sufferers and researchers alike for a while concerning the potential exercise of cannabinoids in treating glioblastomas.

‘We’re actually excited that this world-first trial right here within the UK may assist speed up these solutions and are so grateful to Leeds Hospitals Charity and so many others internationally who’re serving to us make this examine attainable.’

Sativex is a cannibanoid medecine manufactured by GW Pharmaceuticals. This mouth spray has just received approval to be launched on the French market, for limited use on patients suffering from multiple sclerosis. (Photo by: BSIP/Universal Images Group via Getty Images)

Bottles of Sativex mouth spray (BSIP/Universal Images Group by way of Getty Images)

The funding marketing campaign was bolstered by a £45,000 donation from Leeds Hospitals Charity.


MORE : Man identified with incurable mind tumour after being despatched to Specsavers as an alternative of GP


MORE : Brain implant interprets paralysed man’s ideas to textual content with 94% accuracy

Latest news

Related news

LEAVE A REPLY

Please enter your comment!
Please enter your name here